Vergelijking

Pramlintid vs. VK2735

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

151126-32-8

geen gegevens

Molecuulmassa

3949.4 g/mol

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pramlintid	VK2735
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Op recept	Niet goedgekeurd

Volledige vermeldingen

Pramlintid

Volledige vermelding →

VK2735

Volledige vermelding →

Frequently asked questions

What is the difference between Pramlintid and VK2735?: Pramlintid is classified as "Metabool", while VK2735 is classified as "Metabool". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pramlintid or VK2735?: The highest available evidence level is "Humane RCT" for Pramlintid and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pramlintid and VK2735 in Germany and the United States?: Duitsland: Pramlintid — Niet goedgekeurd, VK2735 — Niet goedgekeurd. Verenigde Staten: Pramlintid — Op recept, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Pramlintid

VK2735

Duitsland

Niet goedgekeurd

Verenigde Staten

Op recept

Niet goedgekeurd

Frequently asked questions

What is the difference between Pramlintid and VK2735?

Pramlintid is classified as "Metabool", while VK2735 is classified as "Metabool". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pramlintid or VK2735?

The highest available evidence level is "Humane RCT" for Pramlintid and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pramlintid and VK2735 in Germany and the United States?

Duitsland: Pramlintid — Niet goedgekeurd, VK2735 — Niet goedgekeurd. Verenigde Staten: Pramlintid — Op recept, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.